Near-Field Photocatalysis: Site-Selective Metal Deposition onto Semiconductor Nanoparticles by Linearly Polarized UV Light

Plasmonic nanofabrication beyond the diffraction limit of light is based on chemical and electrochemical reactions induced by plasmonic near field, and it has been applied to the construction of functional nanomaterials and nanodevices. Generation of optical near field is possible even at nonplasmonic dielectric nanostructures including semiconductors. In the present work, we employed In:ZnO as a semiconductor photocatalyst. Hexagonal In:ZnO nanoplates were adsorbed onto a glass plate and irradiated with linearly polarized UV light to drive reductive deposition of Ag. The optical near field induced by the polarized light gave site-selective Ag deposition and, thereby, optical anisotropy reflected by linear dichroism (LD) signals. The optical anisotropy was not introduced by unpolarized UV light. The LD spectra were successfully reproduced by electromagnetic simulations

Magneto-Plasmonic Response Enhancement of Au@Fe₂O₃ Nanocomposites Fabricated by Plasmon-Induced Charge Separation

Here, we developed magneto-plasmonic Au@Fe2O3 core–shell nanocomposites by plasmonic photocatalysis, and we observed enhanced magnetic circular dichroism (MCD). Plasmonic Au nanoparticles were adsorbed onto TiO2 and exposed to visible light in a solution containing Fe2+, and FeOOH was deposited photocatalytically on the Au nanoparticles due to plasmon-induced charge separation. MCD and extinction of the Au nanoparticles at ∼640 nm were enhanced, and their enhancement factors were almost the same, because both of them were due to the increased local refractive index around the Au core. After the nonmagnetic FeOOH shells on the Au cores were converted to magnetic α-Fe2O3 by aerobic annealing, MCD was enhanced further, and its enhancement factor was higher than that of the extinction. This surplus enhancement of MCD is explained in terms of local enhancement of an external magnetic field applied during the MCD measurements by the magnetic α-Fe2O3 shell

Supplementary Figure 2 from Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells

Mutation signature correlation graph</p

Supplementary Methods from Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells

Supplementary methods</p

Supplementary Figure 1 from Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells

Rare and low heteroplasmic mutations frequency and mutation (%) fraction graphs</p

Supplementary Figure 3 from Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells

g Score sum graph</p

Supplementary Tables 1-7 from Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells

Seven supplementary tables. Table S1. Data yield and Duplex Sequencing statistics. Table S2. Mutation contexts significantly differ between normal stem cells and transformed cells. Table S3. Homoplasmic variants in the whole mtDNA identified using Duplex Sequencing. Table S4. Rare variants in the whole mtDNA of HBEC identified using Duplex Sequencing. Table S5. Mutations that are clonally expanded or negatively selected toward tumorigenesis. Table S6. Distribution of nonsynonymous mutations of rare variants in the whole mtDNA and within mtDNA coding regions. Table S7. The number of non-synonymous mutations of rare variants in mitochondrial protein-coding regions.</p

Supplementary Figure legends from Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells

Figure legends for Supplementary figures 1, 2, and 3</p

DataSheet_2_Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.pdf

IntroductionTo investigate the effects of hepatic arterial infusion chemotherapy (HAIC) with or without systemic chemotherapy compared to systemic chemotherapy alone in patients with locally advanced hepatocellular carcinoma (HCC).MethodsFollowing a registered protocol (PROSPERO 2023 CRD42023386780 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023386780), a comprehensive search was performed using reputable databases and registries up to December 26, 2022, with no language, publication date, or status restrictions. Only randomized controlled trials (RCTs) investigating the effects of HAIC with or without systemic chemotherapy versus systemic therapy alone were included. The primary outcomes were overall survival (OS), progression-free survival (PFS), and adverse events. The secondary outcomes included the objective response rate (ORR) and disease control rate (DCR). A random-effects model was used, and the certainty of the evidence was rated using GRADE.ResultsSeven RCTs involving 1,010 patients were included. All trials utilized sorafenib as the comparator. Five trials (690 patients) compared HAIC plus sorafenib to sorafenib alone, while two trials (320 patients) compared HAIC to sorafenib. The results indicate that HAIC, with or without sorafenib, may increase OS, PFS, and ORR compared with sorafenib alone. HAIC may enhance DCR, but the evidence is very uncertain. Adverse events were comparable between HAIC plus sorafenib and sorafenib alone. However, adverse events might be decreased in HAIC alone.DiscussionHAIC with or without systemic chemotherapy may improve survival outcomes and response rates of patients with HCC. Since the current body of evidence is moderate to very low, more robust randomized trials are needed to confirm the efficacy of HAIC.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=386780, identifier CRD42023386780.</p

DataSheet_1_Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.pdf

IntroductionTo investigate the effects of hepatic arterial infusion chemotherapy (HAIC) with or without systemic chemotherapy compared to systemic chemotherapy alone in patients with locally advanced hepatocellular carcinoma (HCC).MethodsFollowing a registered protocol (PROSPERO 2023 CRD42023386780 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023386780), a comprehensive search was performed using reputable databases and registries up to December 26, 2022, with no language, publication date, or status restrictions. Only randomized controlled trials (RCTs) investigating the effects of HAIC with or without systemic chemotherapy versus systemic therapy alone were included. The primary outcomes were overall survival (OS), progression-free survival (PFS), and adverse events. The secondary outcomes included the objective response rate (ORR) and disease control rate (DCR). A random-effects model was used, and the certainty of the evidence was rated using GRADE.ResultsSeven RCTs involving 1,010 patients were included. All trials utilized sorafenib as the comparator. Five trials (690 patients) compared HAIC plus sorafenib to sorafenib alone, while two trials (320 patients) compared HAIC to sorafenib. The results indicate that HAIC, with or without sorafenib, may increase OS, PFS, and ORR compared with sorafenib alone. HAIC may enhance DCR, but the evidence is very uncertain. Adverse events were comparable between HAIC plus sorafenib and sorafenib alone. However, adverse events might be decreased in HAIC alone.DiscussionHAIC with or without systemic chemotherapy may improve survival outcomes and response rates of patients with HCC. Since the current body of evidence is moderate to very low, more robust randomized trials are needed to confirm the efficacy of HAIC.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=386780, identifier CRD42023386780.</p